Influx Healthtech Limited — Investor Meet, 22-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Influx Healthtech presented its investor update, announcing FY25 revenue grew 5% to ₹104.9 Cr. EBITDA jumped 22% to ₹20.6 Cr (19.6% margin), and PAT rose 20% to ₹13.4 Cr (12.8% margin), marking all-time highs. The company expanded its product portfolio by 6% to 3,559 items, including new pet food lines. Management plans significant capacity expansion, leveraging ₹38 Cr from IPO proceeds for new nutraceutical and veterinary facilities, aiming for a 2.5x capacity increase. Focus remains on a diversified portfolio, innovation, and digital growth. Sentiment appears positive.